source
- AbbVie halts development of livmoniplimab after deeming benefit limitedAbbVie announced it is discontinuing the phase 2 development of its monoclonal antibody livmoniplimab (ABBV-151) after concluding the drug is unlikely to outperform existing therapies. The drug wa…
- GE HealthCare launches Allia Celeo ceiling-mounted AI image guidance system at TCT 2026GE HealthCare introduced a new imaging product called Allia Celeo. The system is mounted on the ceiling and uses artificial intelligence to guide image acquisition during procedures. The debut…